"Ionis announces design for Phase III trial of Angelman syndrome therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy ... In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion. Do not ...

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on KROS stock, giving a Buy rating on November 5. Tyler Van Buren has ...

Coherus Biosciences ( (CHRS) ) has released its Q3 earnings. Here is a breakdown of the information Coherus Biosciences presented to its ...

Stanford Medicine researchers discovered that extrachromosomal DNA (ecDNA) significantly drives cancer growth. By analyzing nearly 15,000 human cancers, they found that ecDNAs impact tumor behavior ...

Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody OAKLAND, Calif. and NANJING, China, Nov. 7, 2024 ...